Publications 2009

1.

Assink MDM , Kiewiet JP, Rozenbaum MH, van den Berg PB, Hak E, Buskens EJ, Wilschut JC, Kroes ACM, Postma MJ.
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination.
Vaccine 2009;27:1119-26.

2.

Bakker DJ , de Jong-van den Berg LTW, Fokkema MR.
Controlled study on folate status following folic acid supplementation and discontinuation in women of child-bearing age.
Annals of Clinical Biochemistry 2009;46:231-4.

3.

Connolly MP , Postma MJ, Silber SJ.
What's on the mind of IVF consumers?
Reproductive BioMedicine Online 2009;19(6):767-9.

4.

Connolly MP , Griesinger G, Ledger W, Postma MJ.
The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment.
Human Reproduction 2009;24(11):2796-800.

5.

Dolk H , Boyd P, Calzolare E, Garne E, Haeusler M, Irgens L, de Jong-van den Berg LTW, Khoshnood LM, Nelen V, de Walle HEK.
The European Surveillance of Congential Anomalies (EUROCAT). What is the "primary" prevention of congential anomalies?
The Lancet 2009;374:8 (letter).

6.

Franklin BD , Taxis K, Barber N.
Parenteral drug errors. Reported error rates are likely to be underestimation.
BMJ 2009;338(b1814):1093-(letter).

7.

de Graaf JD , Kajja I, Bimenya GS, Postma MJ, Smit Sibinga CTh.
Bedside practice of blood transfusion in a large teaching hospital in Uganda: An observational study.
Asian J Transf Sci 2009;3(2):60-5.

8.

Geurts MME , Pot JLW, Schepers EH, Tromp C, Colijn CG, Dijkstra A, de Gier JJ.
The evaluation of an intervention based on the application of patient self-completion concordance forms in Dutch community pharmacies and the effect on adherence to chronic medication.
Patient Education and Counseling 2009;78(1):85-90.

9.

Al Hadithy AFY , Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JRBJ, Wilffert B, Bruggeman R, Loonen AJM.
Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.
Progress in Neuro-psychopharmacology & Biological Psychiatry 2009;33:475-81.

10.

Al Hadithy AFY , Wilffert B, Bruggeman R, Stewart RE, Brouwers JRBJ, Matroos GE, Hoek HW, van Harten PN.
Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: The Caracao Extrapyramidal Syndrome study X.
Hum Psychopharmacol Clin Exp 2009;24(2):123-8.

11.

van der Heide DC , van der Putten AAJ, van den Berg PB, Taxis K, Vlaskamp C.
The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities.
Journal of Intellectual Disability Research 2009;53 part 2:161-8.

12.

van Hulst M , Hubben GAA, Sagoe KWC, Promwong PP, Fongsatitkul L, Glynn DM, Sibinga CTS, Postma MJ.
Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands.
Transfusion 2009;49(12):2729-42

13.

van Hunsel F , Passier A, van Grootheest AC.
Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example.
Br J Clin Pharmacol 2009;67(5):558-564.

14.

de Jong J , van den Berg PB, Visser ST, de Vries TW, de Jong-van den Berg LTW.
Antibiotic usage, dosage and course length in children between 0 and 4 years.
Acta Paediatrica 2009;98:1142-8

15.

Lugnér AK , Postma MJ.
Investments decisions in influenze pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
European Journal of Public Health 2009;19(5):516-20.

16.

Postma MJ , de Vries R, Roord J.
Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.
Vaccine 2009;27:7242-3(Letter).

17.

Postma MJ , de Zeeuw D.
The economic benefits of preventing end-stage renal disease in patients with type 2 diabetis mellitus.
Nephrology Dialiysis Transplantation 2009;24(10):2975-83.

18.

Postma MJ .
International society for pharmacoeconmics & outcomes research (ISPOR) conference.
Expert Rev Pharmacoeconomics Outcomes Res 2009;9(4):305-7.

19.

Postma MJ. The dynamic field of Pharmacoeconomics. Expert Rev Clin Pharmacol 2009;2(2):125-7.

20.

Ravera S , Hummel SA, Stolk RP, Heerdink ER, de Jong-van den Berg LTW, de Gier JJ.
The use of driving impairing medicines: a European survey.
Eur J Clin Pharmacol 2009;65:1139-47.

21.

Reinders MK , van Roon EN, Jansen TLTA, Delsing J, Griep EN, Hoekstra M, van de Laar MAFJ, Brouwers JRBJ.
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Annals of the Rheumatic Diseases 2009;68:51-6.

22.

Reinders MK , Haagsma C, Jansen TLTA, van Roon EN, Delsing J, van de Laar MAFJ, Brouwers JRBJ.
A randomised controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Ann Rheum Dis 2009;68(6):892-7

23.

Rogoza RM , Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaption of an existing cohort model to the situation in the Netherlands.
Vaccine 2009;27(35):4776-83.

24.

van Roon EN , van den Bemt PMLA, Jansen TLTA, Houtman NM, van de Laar MAFJ, Brouwers JRBJ.
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
Clinical Therapeutics 2009;31(8):1737-46.

25.

Schorr SG , Slooff CJ, Bruggeman R, Taxis K.
Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands.
Journal of Clinical Psychopharmacology 2009;29(4):399-401.

26.

Schorr SG , Slooff CJ, Bruggeman R, Taxis K.
The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.
Jounrnal of psychiatric research 2009;43(13):1106-11.

27.

Trip A-M , Visser ST, Kalverdijk LJ, de Jong-van den Berg LTW.
Large increase of the use of psycho-stimulans among youth in the Netherlands between 1996 and 2006.
British Journal of Clinical Pharmacology 2009;67(4):466-8.

28.

Tu HAT , Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ.
Economic evaluations of hepatitis B vaccination for developing countries.
Expert Review Vaccines 2009;8(7):907-20.

29.

Vegter S , Kölling P, Töben M, Visser ST, de Jong-van den Berg LTW.
Replacing hormone therapy - is the decline in describing sustained, and are nonhormonal drugs substituted?
The Journal of the North American Menopause Society 2009;16(2):329-35.

30.

Vegter S , Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis GJ, Postma MJ.
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE indertion/deletion polymorphism.
Pharmacogenetics and Genomics 2009;19(9):695-703.

31.

Ververs TF , van Wensen K, Freund MW, van der Heide M, Visser GHA, Schobben AFAM, de Jong-van den Berg LTW, Egberts ACG.
Association between antidepressant drug use during pregnancy and child healthcare utilisation.
International Journal of Obstetrics and Gynaecology BJOG 2009;116(12):1568-77.

32.

de Vries R , Klok RM, Brouwers JRBJ, Postma MJ.
Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health.
Vaccine 2009;27:846-52.

33.

de Vries TW , van den Berg PB, Duiverman EJ, de Jong-van den Berg LTW.
Effect of a minimal pharmacy intervention on improvement of adherence to asthma guidelines.
Archives of Disease in Childhood 2009;95:302–304

34.

Wilffert B , al Hadithy AFY, Sing VJ, Matroos GE, Hoek HW, van Os J, Bruggeman R, Brouwers JRBJ, van Harten PN.
The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment.
Journal of Psychopharmacology 2009;23(6):652-9.

35.

Wirtz VJ , Taxis K, Dreser A.
Pharmacy customers' knowledge of side effects of purchased medicines in Mexico.
Tropical Medicine and International Health 2009;14(1):93-100.

40.

Zijtregtop EAM , Wilschut J, Koelma N, van Delden JJM, Stolk RP, Van Steenbergen J, Broer J, Wolters B, Postma MJ, Hak E.
Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine?
Vaccine 2009;28(1):207-27.

1.

Duyvendak M, Veldhuis GJ.
Vitamine B12-suppletie liever oraal dan parenteraal.
Ned Tijdschr Geneesk 2009;153(B485):1-5.

2.

Galyuk TM, de Backer G, de Jong CAJ, Beers E, Loonen AJM.
Misbruik van Quetiapine. Twee verslaafden patiënten met een borderlinepersoonlijkheidsstoornis.
Ned Tijdschr Geneesk 2009;153(B102):1-3.

3.

Gouverneur BJGM, de Jong-van den Berg LTW.
Insuline-analoga en zwangerschap.
Pharmaceutisch Weekblad Wetenschappelijk Platform 2009;3(3):42-8.

4.

Maurer JM, Kouwen S, Woerdenbag HJ, Brouwers JRBJ, Kosterink JGW, Schellekens RCA.
Farmacotherapeutische rationaliteit van apatheekbereidingen: evaluatie en toepasbaarheid van de LNA-procedure Farmacotherapeutische plaatbepaling apotheekbereiding.
Pharmaceutisch Weekblad Wetenschappelijk Platform 2009;3(12):217-22.

5.

van Noord E, van der Graaf CJ, de Gier JJ.
Onderzoek naar prescriptie-interventies in een openbare apotheek.
Pharmaceutisch Weekblad Wetenschappelijk Platform 2009;3(6):102-7.

6.

Westra TA, Daemen T, Postma MJ, Wilschut J.
Doelmatigheid van Humaan papillomavirus-vaccinatie. Ned Tijdschr Geneesk 2009;153(A356):1-6.

1.

Brouwers JRBJ.
Protonpompremmers: balans na 20 jaar. Blockbusters blijken breed inzetbaar.
Pharmaceutisch Weekblad 2009;april:22-3.

2.

Brouwers JRBJ, Vonkeman HE.
NSAIDs bij de oudere patient, risico's en voorzorgen.
Patient Care 2009;36(4):21-4.

3.

Brouwers JRBJ, Vogel D, ten Have P, van Asselt D.
IJzergebreksanemie bij Ouderen.
Tijdschrift voor Medische Nascholing Patient Care (Belgie) 2009;2:7-12.

4.

van Dijk KN, van Asselt DZB, Vogel D, van der Hooft CS, van Roon EN, Brouwers JRBJ.
Interventies na een gestructureerde medicatie-analyse door klinisch geriater en ziekenhuisapotheker bij klinisch opgenomen kwetsbare oudere patiënten.
Tijdschrift voor Gerontologie en Geriatrie 2009;40(april):72-8.

5.

Taxis K, Brouwers JRBJ, Mulder H, Bruggeman R.
Medicatiereview bij patiënten met psychiatrische aandoeningen.
Psyfar 2009;4(2):45-9.

1.

Buurma H, Beudeker HJ, de Jong-van den Berg LTW, Leufkens HGM.
Het Geneesmiddel.
5e, herziene druk ed. Maarssen: Elzevier gezondheidszorg, 2009

2.

de Gier JJ.
Commentaren Medicatiebewaking. 2009/2010
ed. Houten: Health Base, 2009

3.

Verster JC, Randi-Perumal SR, Ramaekers JG, de Gier JJ.
Drugs, Driving and Traffic Safety.
Basel: Birkhäuser Verlag AG, 2009

1.

Bos JM, Postma MJ.
Economics and Vaccines.
In: Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. 2009:1336-50.

2.

Brouwers JRBJ.
Klinische farmacie en klinische farmacologie in de ziekenhuisfarmacie.
In: Kutch Loyenga et al., ed. De NVZA op weg naar de toekomst: Een geschiedenis. 2009:37-40.

3.

Buurma H, de Gier JJ, Egberts ACG.
De apotheker als zorgverlener.
In: Buurma H, Beudeker HJ, de Jong-van den Berg LTW, Leufkens HGM, eds. Het geneesmiddel. 5 ed. Maarssen: Elsevier, 2009:137-60.

4.

de Gier JJ, Alvarez FJ, Mercier-Guyon Ch, Verstraete AG.
Prescribing and dispensing guidelines for medicinal drugs affecting driving performance.
In: Verster JJ et al, ed. Drugs, Driving and Traffic Safety.Basel: Birkhäuser Verlag AG, 2009:121-34.

5.

de Jong-van den Berg LTW, de Smit DJ.
Communicatie.
In: Buurma H, Beudeker HJ, de Jong-van den Berg LTW, Leufkens HGM, eds. Het geneesmiddel. 5 ed. Maarssen: Elsevier, 2009:181-200.

6.

Meijer I, Vos R, de Jong-van den Berg LTW, Meijer DKF.
Orphan drugs.
Volksgezondheid Toekomst Verkenning.Bilthoven: RIVM, 2009:505-20.

7.

Postma MJ, van Hulst M.
Net Monetary Benefit.
In: Kattan MW, ed. Encyclopedia of Medical Decision Making.Ohio: Sage Publications, 2009.

8.

Postma MJ.
Sensitivity Analysis.
In: Renée JG Arnold, ed. Pharmacoeconomics. From theory tp practice.New York: Taylor & Francis Group, 2009:163-74.

9.

Toenders WGM, Postma MJ.
De vergoeding van geneesmiddelen. Goedkoop als het kan, duur als het moet.
In: Buurma H, Beudeker HJ, de Jong-van den Berg LTW, Leufkens HGM, eds. Het geneesmiddel. 5 ed. Maarssen: Elsevier, 2009:83-99.

10.

de Vries CS, de Jong-van den Berg LTW.
Spontane rapportage en farmaco-epidemiologie.
In: Buurma H, Beudeker HJ, de Jong-van den Berg LTW, Leufkens HGM, eds. Het geneesmiddel. 5 ed. Maarssen: Elsevier, 2009:201-20.